Global Antiulcerant Drugs Market Size By Type (Proton Pump Inhibitors, H2 Receptor Antagonists), By Application (Mouth Ulcers, Stomach Ulcers), By Region, And Segment Forecasts, 2023 to 2032

The Global Antiulcerant Drugs Market was valued at USD 28.4 billion in 2023 and is projected to reach USD 42.1 billion by 2031, growing at a CAGR of 5.1% during the forecast period from 2023 to 2031. The market is driven by the rising prevalence of gastrointestinal disorders, including peptic ulcers and gastroesophageal reflux disease (GERD), as well as the increasing consumption of non-steroidal anti-inflammatory drugs (NSAIDs). The widespread use of proton pump inhibitors (PPIs), histamine-2 (H2) receptor antagonists, and antacids for both prescription and over-the-counter treatment continues to expand market opportunities across developed and emerging economies.

Drivers:

Rising Prevalence of Gastrointestinal Disorders

An increase in conditions such as GERD, Zollinger-Ellison syndrome, and peptic ulcers—particularly due to sedentary lifestyles, unhealthy diets, stress, and Helicobacter pylori infections—is significantly boosting demand for antiulcerant drugs worldwide.

Growing Geriatric Population

The aging population, more prone to gastrointestinal complications, often requires long-term acid suppression therapy. This demographic trend is fueling demand for antiulcer medications.

Over-the-Counter (OTC) Availability and Self-Medication Trends

The ease of access to OTC antiulcerants such as antacids and low-dose PPIs has encouraged self-medication, especially in urban settings, further expanding market penetration.

Restraints:

Side Effects and Long-Term Risks

Prolonged use of PPIs and H2 receptor blockers has been associated with risks such as nutrient malabsorption, kidney issues, and increased susceptibility to infections like Clostridium difficile, restraining their long-term use.

Patent Expiry and Generic Competition

Several blockbuster antiulcer drugs have lost patent protection, leading to a surge in generics and price erosion, affecting the revenue streams of major pharmaceutical companies.

Opportunity:

Emerging Markets and Telehealth Expansion

Untapped potential in emerging markets such as Southeast Asia and Sub-Saharan Africa, coupled with increasing digital health adoption, presents significant opportunities for expanding distribution and access to antiulcer therapies.

Development of Targeted and Combination Therapies

Ongoing R&D into more targeted treatment options, including novel drug combinations with fewer side effects and better patient compliance, presents growth potential for innovative pharmaceutical players.

Market by System Type Insights:

By drug class, Proton Pump Inhibitors (PPIs) dominated the market in 2023, holding over 40% of the revenue share. Their efficacy in long-term acid suppression has made them a preferred treatment option globally. However, Potassium-competitive acid blockers (P-CABs) are emerging as a high-growth segment, owing to rapid symptom relief and lower side effect profiles.

Market by End-use Insights:

In terms of end use, hospital pharmacies held the largest market share in 2023, owing to high-volume prescriptions and inpatient treatments for gastrointestinal complications. Meanwhile, retail and online pharmacies are expected to grow significantly, driven by increased consumer self-awareness and digital health integration.

Market by Regional Insights:

Geographically, North America led the global antiulcerant drugs market in 2023, accounting for over 35% of the total revenue, due to high disease prevalence, established healthcare infrastructure, and favorable reimbursement policies. Asia-Pacific is projected to register the fastest growth, supported by expanding healthcare access, growing awareness, and lifestyle shifts leading to rising GERD and ulcer incidences.

Competitive Scenario:

Key players in the global antiulcerant drugs market include Pfizer Inc., AstraZeneca PLC, Takeda Pharmaceutical Co., GlaxoSmithKline plc, Sanofi S.A., Eisai Co. Ltd., Dr. Reddy’s Laboratories, Novartis AG, Sun Pharmaceutical Industries Ltd., and Boehringer Ingelheim GmbH. Strategic initiatives such as product innovation, partnerships, and generic launches continue to shape the competitive landscape.

Scope of Work – Global Antiulcerant Drugs Market

Report Metric Details

Market Size (2023) USD 28.4 billion

Projected Market Size (2031) USD 42.1 billion

CAGR (2023-2031) 5.1%

Market Segments By Drug Class (PPIs, H2 Receptor Antagonists, Antacids, P-CABs), End-use

Growth Drivers Increasing prevalence of GI disorders, rising geriatric population

Opportunities Growth in emerging markets, development of new targeted combination therapies

Key Market Developments:

June 2023: Takeda launched a new P-CAB therapy in Japan and South Korea, showing improved efficacy and faster symptom control compared to traditional PPIs.

January 2024: AstraZeneca announced a collaboration with a digital therapeutics company to develop AI-driven diagnostics for early GERD detection.

August 2023: Dr. Reddy’s Laboratories received FDA approval for a generic version of Dexilant (dexlansoprazole), expanding its North American portfolio.

FAQs

1. What is the current market size of the Global Antiulcerant Drugs Market?

The market was valued at USD 28.4 billion in 2023.

2. What is the major growth driver of the Global Antiulcerant Drugs Market?

The rising prevalence of gastrointestinal disorders, particularly GERD and peptic ulcers, is the major growth driver.

3. Which is the largest region during the forecast period in the Global Antiulcerant Drugs Market?

North America holds the largest regional share, driven by high disease incidence and strong healthcare systems.

4. Which segment accounted for the largest market share in the Global Antiulcerant Drugs Market?

The Proton Pump Inhibitors (PPIs) segment accounted for the largest share in 2023.

5. Who are the key market players in the Global Antiulcerant Drugs Market?

Key players include Pfizer, AstraZeneca, Takeda, GlaxoSmithKline, Sanofi, and Dr. Reddy’s Laboratories.